

Supplementary Appendix 4C Announcement

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), provides the following information as a supplementary announcement to the Appendix 4C released on 28 January 2022, in accordance with ASX Listing Rule 4.7C.1, to provide a summary of the expenditure incurred on business activities:

- Research and development payments were \$329,000 (Q1: \$324,000)
- Advertising and Marketing payments increased to \$199,000 (Q1: \$127,000)
- Staff Costs payments decreased to \$1,012,000 (Q1: \$1,055,000)
- Administration and Corporate costs increased to \$1,774,000 (Q1: \$544,000). In quarter 2 was a \$1,321,059 payment for a payroll tax assessment relating to 2017, there are no further payments due under that assessment and PainChek is currently objecting to the assessment. The remaining increase in costs is timing of annual insurance premiums and costs of newly implemented customers.
- In accordance with ASX Listing Rule 4.7C.3, the company made payments to directors during the period of \$102,500: \$40,000 to non executive and \$62,500 to executive directors.

This announcement has been authorized for release by CEO Philip Daffas.

For more information:

Sally McDow
Company Secretary, PainChek
sally.mcdow@boardroomlimited.com.au
0420 213 035

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies. Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere. PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com